Athera Biotechnologies AB
πΈπͺSweden
- Country
- πΈπͺSweden
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://athera.se
Clinical Trials
9
Active:5
Completed:3
Trial Phases
2 Phases
Phase 1:5
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)β’ Click on a phase to view related trials
Phase 1
5 (55.6%)Phase 2
4 (44.4%)Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
Phase 2
Completed
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- Drug: ATH3G10Drug: Placebo
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Athera Biotechnologies AB
- Target Recruit Count
- 82
- Registration Number
- NCT03991143
- Locations
- πΈπͺ
Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden
Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a
Phase 2
Terminated
- Conditions
- Arterial InflammationCardiovascular Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Athera Biotechnologies AB
- Target Recruit Count
- 10
- Registration Number
- NCT03320265
- Locations
- π³π±
Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands
πΈπͺCTC Clinical Trial Consultants AB, Uppsala, Sweden
News
No news found